Ardelyx: Strong Execution, Fairly Valued [Seeking Alpha]
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference [Yahoo! Finance]
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Ardelyx First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]